Skip to content

A randomized controlled study of ovulation induction regimen versus antagonist regimen in a hyperprogesterone state in assisted reproduction in a population of Poseidon Group 4

A randomized controlled study of ovulation induction regimen versus antagonist regimen in a hyperprogesterone state in assisted reproduction in a population of Poseidon Group 4

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095538
Enrollment
Unknown
Registered
2025-01-08
Start date
2025-01-10
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

PPOS solution group:Ovulation induction treatment using the PPOS protocol
Antagonist protocol group:Treatment with antagonist regimens for ovulation induction

Sponsors

The First People's Hospital of Yunnan Province
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
35 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) female aged 35-45 years; (2) clinical diagnosis of infertility; (3) ovarian reserve function: AMH < 1.2ng/mL, AFC < 5; (4) planned to receive IVF/ICSI treatment; (5) patients voluntarily participated in the study and signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) known to be allergic to the main ingredients or excipients of Anxinbao (recombinant human follicle stimulating hormone for injection); (2) polycystic ovary syndrome; (3) malignant tumors of hypothalamus, pituitary, ovary, uterus or breast; (4) abnormal uterine bleeding; (5) severe intrauterine adhesions, adenomyosis and other diseases affecting embryo implantation; (6) acute infection of urinary and reproductive system; (7) history of recurrent spontaneous abortion; (8) uncontrolled systemic diseases, endocrine diseases or metabolic abnormalities that affect pregnancy outcomes; (9) stage ?-? endometriosis; (10) syphilis, AIDS; (11) smoking and drinking heavily; (12) patients undergoing preimplantation genetic screening (PGS)/preimplantation genetic diagnosis (PGD); (13) other circumstances judged by the investigator as not suitable for participating in this clinical study.

Design outcomes

Primary

MeasureTime frame
Clinical pregnancy rate;Cumulative pregnancy rate;

Secondary

MeasureTime frame
Number of days that GN is used;The total amount of GN used;Blood luteinizing hormone (LH) level of HCG day;Blood estradiol (E2) level of HCG day;Early-onset LH peak;Early ovulation rate;Unavailable embryo rate;Cycle cancellation rate;Number of ovums retrieved;The number of embryos available;MII ovum Rate;2PN fertilization rate;2PN cleavage rate;High quality embryo rate;Clinical pregnancy rate in the first transplant cycle;

Countries

China

Contacts

Public ContactWu Ze

The First People's Hospital of Yunnan Province

54903455@qq.com+86 130 3337 9201

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026